NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Friday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase 90,000 additional shares of its stock at $10 per share.

As a result, the total gross proceeds from the offering are expected to be $6.9 million, Cancer Genetics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.